These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12871198)

  • 1. Proteolytic events of HIV-1 replication as targets for therapeutic intervention.
    Tözsér J; Oroszlan S
    Curr Pharm Des; 2003; 9(22):1803-15. PubMed ID: 12871198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stages of HIV replication and targets for therapeutic intervention.
    Tözsér J
    Curr Top Med Chem; 2003; 3(13):1447-57. PubMed ID: 14529520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
    Martinez ZS; Castro E; Seong CS; Cerón MR; Echegoyen L; Llano M
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5731-41. PubMed ID: 27431232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.
    Druillennec S; Dong CZ; Escaich S; Gresh N; Bousseau A; Roques BP; Fournié-Zaluski MC
    Proc Natl Acad Sci U S A; 1999 Apr; 96(9):4886-91. PubMed ID: 10220388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
    Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
    J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV inhibitors: problems and reality.
    Tözsér J
    Ann N Y Acad Sci; 2001 Nov; 946():145-59. PubMed ID: 11762983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.
    Berkhout B
    J Biomed Sci; 1999; 6(5):298-305. PubMed ID: 10494036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of HIV-1 protease.
    Meek TD
    J Enzyme Inhib; 1992; 6(1):65-98. PubMed ID: 1285304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
    Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
    Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.
    Whitehurst N; Chappey C; Petropoulos C; Parkin N; Gamarnik A
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):779-84. PubMed ID: 14585208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.
    Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M
    FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
    Voshavar C
    Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.